Cardiology

33-48 of 306

FAI and the Future of Cardiac Risk Stratification
FAI and the Future of Cardiac Risk Stratification
Heart Matters
FAI and the Future of Cardiac Risk Stratification
Redefining ATTR-CM Care in the Age of Targeted Therapy
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CM
Redefining ATTR-CM Care in the Age of Targeted Therapy
- Steve Jackson, PharmD
- David Rind, MD, MSc
Tracking Disease Progression in ATTR-CM
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CM
Tracking Disease Progression in ATTR-CM
- Ryan Quigley
- Joban Vaishnav, MD
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CM
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
- Steve Jackson, PharmD
- Karola Jering, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CM
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
- Shelina Ramnarine, PhD
- Chadi Alraies, MD, MPH, FACC
Can AI Transform How We Diagnose ATTR-CM?
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CM
Can AI Transform How We Diagnose ATTR-CM?
- Ryan Quigley
- Frederick Ruberg, MD
MinuteCE®
The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
0.75 credits 5 episodes
- Javed Butler, MD
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD
0.75 credits 5 episodes
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
MinuteCE®
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
0.75 program credits
- Javed Butler, MD
- Carolyn S. P. Lam, MBBS, PhD
0.75 program credits
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CE
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
0.25 credits
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD
0.25 credits
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CM
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
- Ryan Quigley
- Ahmad Masri, MD, MS
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
CME/CE
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
0.25 credits
- Stephen J. Greene, MD, FACC, FHFSA
- Gianluigi Savarese, MD
0.25 credits
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CM
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
- Ryan Quigley
- Kevin Alexander, MD
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander

3/8

33-48 of 306

Title

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy